Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmaCyte BiotechPMCB -0.78%32 EV-to-EBITDA is 2.46 as of Jul. 24, 2026. GuruFocus rates PMCB with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 402 Biotechnology companies, PharmaCyte Biotech ranks better than 70.65% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PharmaCyte Biotech's enterprise value is $-13.22 Mil.
PharmaCyte Biotech's EBITDA for the trailing twelve months (TTM) ended in Jan. 2026 was $-5.38 Mil. Therefore, PharmaCyte Biotech's EV-to-EBITDA for today is 2.46.
The historical rank and industry rank for PharmaCyte Biotech's EV-to-EBITDA or its related term are showing as below:
PMCB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0 Max: 2.49
Current: 2.46
During the past 13 years, the highest EV-to-EBITDA of PharmaCyte Biotech was 2.49. The lowest was 0.00. And the median was 0.00.
PMCB's EV-to-EBITDA is ranked better than 70.65% of 402
companies
in the Biotechnology industry
Industry Median: 12.2
vs PMCB: 2.46
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PharmaCyte Biotech's PE Ratio (TTM) for today is calculated as:
PharmaCyte Biotech's share price for today is $0.6001.
PharmaCyte Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.120.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for PharmaCyte Biotech's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, PharmaCyte Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCyte Biotech EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PharmaCyte Biotech's EV-to-EBITDA falls into.
PharmaCyte Biotech's current Enterprise Value is $-13.22 Mil.
PharmaCyte Biotech's EBITDA for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.38 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaCyte Biotech (PMCB) has a EV-to-EBITDA of 2.46 as of Jul. 24, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PharmaCyte Biotech. According to the industry distribution chart, PharmaCyte Biotech ranks #118 out of 402 companies in the Biotechnology industry, placing it in the top 29.4%.
Is PharmaCyte Biotech's EV-to-EBITDA too high?
PharmaCyte Biotech's current EV-to-EBITDA is 2.46. The Biotechnology industry median EV-to-EBITDA is 12.20. PharmaCyte Biotech's value of 2.46 is 79.8% below this industry median. Based on the distribution chart, PharmaCyte Biotech ranks #118 out of 402 companies in the Biotechnology industry, which is above the industry midpoint. Overall, PharmaCyte Biotech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's EV-to-EBITDA compare to ERNA and SYBX?
According to the Biotechnology industry distribution chart, PharmaCyte Biotech ranks #118 out of 402 companies for EV-to-EBITDA. This puts PharmaCyte Biotech in the upper half of its industry. The industry median EV-to-EBITDA is 12.20. PharmaCyte Biotech's value of 2.46 is 79.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.20, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaCyte Biotech's current EV-to-EBITDA of 2.46 is 79.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PharmaCyte Biotech. For the Biotechnology industry, the median EV-to-EBITDA is 12.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCyte Biotech's current EV-to-EBITDA is 2.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current EV-to-EBITDA of 2.46. The current EV-to-EBITDA is 2.46 and 79.8% below the Biotechnology industry median of 12.20. PharmaCyte Biotech's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current EV-to-EBITDA is 2.46 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
32GF Score
Get the complete analysis for PMCB
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMCB has been successfully added to your 
